Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Eyes Emerging Biosimilars Market In Japan

This article was originally published in The Pink Sheet Daily

Executive Summary

The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.

You may also be interested in...



Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers

Following Pfizer's step, Daiichi Sankyo is venturing into the generic drug business in Japan. The third-largest domestic branded drug maker Feb. 26 announced the establishment of generic subsidiary Daiichi Sankyo Espha, and a plan to start marketing products beginning in October. The announcement has stirred up a shock wave across the industry

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan

Merck Adds Biosimilar Capabilities, Insmed Gets Fresh Start In $130M Deal

A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel